Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity.

Cytokine
O OsbornT Bartfai

Abstract

The proinflammatory cytokine Interleukin 1 beta (IL-1beta) is elevated in obese individuals and rodents and it is implicated in impaired insulin secretion, decreased cell proliferation and apoptosis of pancreatic beta cells. In this study we describe the therapeutic effects by an IL-1beta antibody to improve glucose control in hyperglycemic mice with diet-induced obesity. After 13 weeks of treatment the IL-1beta antibody treated group showed reduced glycated hemoglobin (( *)P=0.049), reduced serum levels of proinsulin (( *)P=0.015), reduced levels of insulin and smaller islet size (( *)P=1.65E-13) relative to the control antibody treated group. Neutralization of IL-1beta also significantly reduced serum amyloid A (SAA) which is an indicator of inflammation-induced acute phase response (( *)P=0.024). While there was no improvement of obesity, a significant improvement of glycemic control and of beta cell function is achieved by this pharmacological treatment which may slow/prevent disease progression in Type 2 Diabetes.

References

May 1, 1990·The Journal of Clinical Investigation·W P ArendS P Eisenberg
Nov 1, 1989·Neuroendocrinology·F BerkenboschH O Besedovsky
Jan 1, 1987·Journal of Neuroscience Research·H Besedovsky, A del Rey
May 1, 1995·The Journal of Clinical Investigation·G S HotamisligilB M Spiegelman
Sep 1, 1996·Diabetologia·T Mandrup-Poulsen
Oct 30, 1998·Journal of Hypertension·E Ferrannini, A Mari
Nov 27, 1999·Drugs·S Del Prato
Mar 13, 2001·Blood Purification·C A Dinarello, B J Pomerantz
Oct 24, 2001·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·A FestaS M Haffner
Jul 11, 2002·Current Opinion in Clinical Nutrition and Metabolic Care·André Marette
Sep 11, 2002·Cytokine & Growth Factor Reviews·William P Arend
Jul 29, 2003·Diabetes·Gunnar EngströmFolke Lindgärde
Apr 3, 2004·Nature Reviews. Drug Discovery·Martin Braddock, Anthony Quinn
Jan 27, 2005·Science's STKE : Signal Transduction Knowledge Environment·Yehiel Zick
Jul 20, 2005·Acta Physiologica Scandinavica·P Trayhurn
Apr 29, 2006·Diabetes·Maria C GarcíaJohn-Olov Jansson
Oct 13, 2006·Proceedings of the National Academy of Sciences of the United States of America·Adriana Del ReyHugo O Besedovsky
Nov 8, 2006·Brain, Behavior, and Immunity·Robert Dantzer, Keith W Kelley
Jul 20, 2007·The New England Journal of Medicine·Saul Malozowski, Jon Todd Sahlroot
Sep 14, 2007·International Journal of Clinical Practice·R P Vincent, C W le Roux

❮ Previous
Next ❯

Citations

May 22, 2013·International Journal of Obesity : Journal of the International Association for the Study of Obesity·H WangR H Eckel
Jun 15, 2011·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Xizhen XuLing Tu
Oct 3, 2013·Frontiers of Medicine·Jichun YangYoufei Guan
Jan 11, 2011·Nature Medicine·Bolormaa VandanmagsarVishwa Deep Dixit
Mar 8, 2012·Nature Medicine·Olivia Osborn, Jerrold M Olefsky
Mar 7, 2012·Cold Spring Harbor Perspectives in Medicine·Justin I Odegaard, Ajay Chawla
Jan 16, 2010·Science·Kate SchroderJurg Tschopp
May 6, 2011·Science Translational Medicine·Seth L MastersLuke A J O'Neill
Nov 30, 2010·International Journal of Endocrinology·Chunjiong WangJichun Yang
Sep 21, 2013·Reviews in Endocrine & Metabolic Disorders·H L KammounM A Febbraio
Mar 13, 2012·Annual Review of Nutrition·Shengyi SunLing Qi
Mar 11, 2011·Genes and Immunity·B S NikolajczykR Gyurko
Jul 17, 2009·Expert Opinion on Biological Therapy·Kathrin MaedlerJoachim Størling
Aug 4, 2009·Archives of Physiology and Biochemistry·Jan A EhsesMarc Y Donath
Jan 25, 2012·Journal of Pharmaceutical Sciences·Muhammad Sajid Hamid AkashShuqing Chen
Jul 8, 2011·Trends in Immunology·Dominic De Nardo, Eicke Latz
Mar 8, 2011·Trends in Molecular Medicine·Seth L Masters, Luke A J O'Neill
Feb 16, 2010·Metabolism: Clinical and Experimental·Mary P MilesSara J Frederickson
Oct 5, 2010·Diabetes/metabolism Research and Reviews·A Roeske-NielsenK Buschard
Apr 14, 2010·International Journal of Experimental Pathology·Huw Bowen JonesRichard Jenkins
Jan 29, 2011·Gastroenterology Research and Practice·Kouichi MiuraDavid A Brenner
Feb 20, 2010·Mediators of Inflammation·Christian JungHans Reiner Figulla
Apr 16, 2014·Diabetes Research and Clinical Practice·S ZiaiM V Richter
Oct 18, 2014·Frontiers in Physiology·Anantha HarijithViswanathan Natarajan
Sep 13, 2014·PloS One·Kimberly A NegrinMichael P Czech
Jun 21, 2016·Scientific Reports·Faiyaz AhmadVincent C Manganiello
Feb 11, 2015·Annual Review of Physiology·Martin ValdearcosSuneil K Koliwad

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis